polyclonal goat anti human il 23 p19 antibody (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
93
Structured Review
R&D Systems
polyclonal goat anti human il 23 p19 antibody
Polyclonal Goat Anti Human Il 23 P19 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/polyclonal+goat+anti+human+il+23+p19+antibody/Human+IL-23+p19+Antibody/pm36054147-20-26-36
Average 93 stars, based on 24 article reviews
Polyclonal Goat Anti Human Il 23 P19 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/polyclonal+goat+anti+human+il+23+p19+antibody/Human+IL-23+p19+Antibody/pm36054147-20-26-36
Average 93 stars, based on 24 article reviews
polyclonal goat anti human il 23 p19 antibody - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Saline:Article Title: Imiquimod-induced ex vivo model of psoriatic human skin via interleukin-17A signalling of T cells and Langerhans cells. Article Snippet: Psoriasis is a chronic inflammatory skin disease characterized by erythematosus and thickening plaques covered by silver scales that can be observed on any part of the body.1 Psoriasis is a global health problem affecting 2%– 3% of the worldwide population.2 The pathogenesis of psoriasis is complex and is not completely understood, but the crosstalk between immune cells (such as T cells and dendritic cells) and epidermal keratinocytes is essential for the development of psoriatic inflammation.3 In addition, the interleukin23 (IL23)/ interleukin17 (IL17) axis is the major immune pathway involved in the pathogenesis of psoriasis.4 In this immune axis, the secretion of interleukin23 by dendritic cells stimulates the production of IL17 by T cells and interferonγ (IFNγ) by Th1 cells, which drives the development of psoriatic skin lesions.5,6 The use of animal models has contributed to elucidating the pathogenic mechanisms involved in Received: 3 May 2022 | Revised: 22 July 2022 | Accepted: 9 August 2022 DOI: 10.1111/exd.14659 Incubation:Article Title: Imiquimod-induced ex vivo model of psoriatic human skin via interleukin-17A signalling of T cells and Langerhans cells. Article Snippet: Psoriasis is a chronic inflammatory skin disease characterized by erythematosus and thickening plaques covered by silver scales that can be observed on any part of the body.1 Psoriasis is a global health problem affecting 2%– 3% of the worldwide population.2 The pathogenesis of psoriasis is complex and is not completely understood, but the crosstalk between immune cells (such as T cells and dendritic cells) and epidermal keratinocytes is essential for the development of psoriatic inflammation.3 In addition, the interleukin23 (IL23)/ interleukin17 (IL17) axis is the major immune pathway involved in the pathogenesis of psoriasis.4 In this immune axis, the secretion of interleukin23 by dendritic cells stimulates the production of IL17 by T cells and interferonγ (IFNγ) by Th1 cells, which drives the development of psoriatic skin lesions.5,6 The use of animal models has contributed to elucidating the pathogenic mechanisms involved in Received: 3 May 2022 | Revised: 22 July 2022 | Accepted: 9 August 2022 DOI: 10.1111/exd.14659 |
